Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics

Using CSF proteomics, Tijms et al. identify three Alzheimer’s disease subtypes that show: 1) hyperplasticity and increased BACE1 levels; 2) innate immune activation; and 3) blood-brain barrier dysfunction with low BACE1 levels. Future therapeutics may need tailoring to individual disease subtypes.

[1]  I. Lindberg,et al.  A comprehensive systematic review of CSF proteins and peptides that define Alzheimer’s disease , 2020, Clinical Proteomics.

[2]  The Lancet Haematology,et al.  Proliferation and differentiation. , 2019, The Lancet. Haematology.

[3]  P. Visser,et al.  Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer’s disease: A literature review , 2019, Critical reviews in clinical laboratory sciences.

[4]  A. Levey,et al.  Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease , 2019, Science Advances.

[5]  Bin Zhang,et al.  Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation , 2019, bioRxiv.

[6]  R. Dobson,et al.  Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset , 2019, bioRxiv.

[7]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[8]  Antonio Núñez Galindo,et al.  Proteomes of Paired Human Cerebrospinal Fluid and Plasma: Relation to Blood-Brain Barrier Permeability in Older Adults. , 2019, Journal of proteome research.

[9]  Genetic,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[10]  Nick C Fox,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[11]  Timothy J. Hohman,et al.  Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk , 2019, Nature Genetics.

[12]  G. Church,et al.  REST and Neural Gene Network Dysregulation in iPSC Models of Alzheimer’s Disease , 2019, Cell reports.

[13]  Melanie A. Huntley,et al.  Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies , 2018, Neuron.

[14]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[15]  W. M. van der Flier,et al.  Atrophy subtypes in prodromal Alzheimer’s disease are associated with cognitive decline , 2018, Brain : a journal of neurology.

[16]  R. Dobson,et al.  The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics , 2018, Alzheimer's Research & Therapy.

[17]  J. Poirier,et al.  Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis , 2018, Journal of Alzheimer's disease : JAD.

[18]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[19]  W. M. van der Flier,et al.  Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results. , 2018, Clinical chemistry.

[20]  K. Blennow,et al.  The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer’s disease , 2018, PloS one.

[21]  Berislav V. Zlokovic,et al.  Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders , 2018, Nature Reviews Neurology.

[22]  W. M. van der Flier,et al.  Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.

[23]  Frederik Barkhof,et al.  Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts , 2017, Alzheimer's & Dementia.

[24]  T. Kanekiyo,et al.  Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease , 2017, International journal of molecular sciences.

[25]  Gary Yellen,et al.  Neuronal Stimulation Triggers Neuronal Glycolysis and Not Lactate Uptake. , 2017, Cell metabolism.

[26]  K. Blennow,et al.  Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. , 2017, Parkinsonism & related disorders.

[27]  P. Scheltens,et al.  Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population , 2017, Alzheimer's Research & Therapy.

[28]  L. Mucke,et al.  Network abnormalities and interneuron dysfunction in Alzheimer disease , 2016, Nature Reviews Neuroscience.

[29]  R. Sperling,et al.  Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer’s disease , 2016, Proceedings of the National Academy of Sciences.

[30]  A. Smit,et al.  Profiling the human hippocampal proteome at all pathologic stages of Alzheimer's disease , 2016, Alzheimer's & Dementia.

[31]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[32]  Kevin L. Boehme,et al.  Assessment of the genetic variance of late-onset Alzheimer's disease , 2016, Neurobiology of Aging.

[33]  Frederik Barkhof,et al.  Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease , 2015, Human brain mapping.

[34]  Daniel S Spellman,et al.  Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF , 2015, Proteomics. Clinical applications.

[35]  P. Scheltens,et al.  Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains , 2015, European Neuropsychopharmacology.

[36]  Pierre J. Magistretti,et al.  A Cellular Perspective on Brain Energy Metabolism and Functional Imaging , 2015, Neuron.

[37]  Jack Euesden,et al.  PRSice: Polygenic Risk Score software , 2014, Bioinform..

[38]  K. Blennow,et al.  SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease , 2014, Molecular Neurodegeneration.

[39]  E. Zanier,et al.  Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis , 2014, Front. Cell. Neurosci..

[40]  J. Olsen,et al.  Off-line high-pH reversed-phase fractionation for in-depth phosphoproteomics. , 2014, Journal of proteome research.

[41]  T. Maniatis,et al.  An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex , 2014, The Journal of Neuroscience.

[42]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[43]  D. Holtzman,et al.  Neuronal activity regulates extracellular tau in vivo. , 2014, The Journal of experimental medicine.

[44]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[45]  Frederik Barkhof,et al.  Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease , 2013, Neurobiology of Aging.

[46]  Anushya Muruganujan,et al.  Large-scale gene function analysis with the PANTHER classification system , 2013, Nature Protocols.

[47]  Leslie M. Shaw,et al.  Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI , 2013, Acta Neuropathologica.

[48]  E. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[49]  Wendy Noble,et al.  Physiological release of endogenous tau is stimulated by neuronal activity , 2013, EMBO reports.

[50]  M. Freedman,et al.  Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome , 2013, Alzheimer's Research & Therapy.

[51]  C. Walsh,et al.  Microcephaly Gene Links Trithorax and REST/NRSF to Control Neural Stem Cell Proliferation and Differentiation , 2012, Cell.

[52]  B. Zlokovic,et al.  Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[53]  D. Purpura,et al.  REST-dependent epigenetic remodeling promotes the in vivo developmental switch in NMDA receptors , 2012, Nature Neuroscience.

[54]  A. Fagan,et al.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. , 2012, Biomarkers in medicine.

[55]  J. Hort,et al.  Evaluation of white matter alterations in Alzheimer's disease and normal pressure hydrocephalus as measured by diffusion weighted MRI , 2012, Alzheimer's & Dementia.

[56]  C. Jack,et al.  MRI in pathologically-defined hippocampal sparing and limbic predominant atypical variants of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[57]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[58]  R. Veerhuis,et al.  Complement in the brain. , 2011, Molecular immunology.

[59]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[60]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[61]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[62]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[63]  Jee Hoon Roh,et al.  Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.

[64]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[65]  Howard Y. Chang,et al.  Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes , 2010, Science.

[66]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[67]  Renaud Gaujoux,et al.  A flexible R package for nonnegative matrix factorization , 2010, BMC Bioinformatics.

[68]  K. Blennow,et al.  CSF biomarkers predict a more malignant outcome in Alzheimer disease , 2010, Neurology.

[69]  Jason H. Moore,et al.  Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans , 2010, Alzheimer's & Dementia.

[70]  T. Beach,et al.  Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects. , 2009, Current Alzheimer research.

[71]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[72]  W. M. van der Flier,et al.  CSF biomarkers in relationship to cognitive profiles in Alzheimer disease , 2009, Neurology.

[73]  A. Blokland,et al.  Human apolipoprotein C-I expression in mice impairs learning and memory functions Published, JLR Papers in Press, December 26, 2007. , 2008, Journal of Lipid Research.

[74]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[75]  M. Esiri,et al.  Protein co-expression with axonal injury in multiple sclerosis plaques , 2006, Acta Neuropathologica.

[76]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[77]  Hilkka Soininen,et al.  Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers , 2005, Annals of neurology.

[78]  G. Mandel,et al.  The many faces of REST oversee epigenetic programming of neuronal genes , 2005, Current Opinion in Neurobiology.

[79]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[80]  J. Poirier,et al.  Apolipoprotein C-I Expression in the Brain in Alzheimer's Disease , 2001, Neurobiology of Disease.

[81]  N. Shachter.  Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism , 2001, Current opinion in lipidology.

[82]  H. Sebastian Seung,et al.  Learning the parts of objects by non-negative matrix factorization , 1999, Nature.

[83]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[84]  J. Rogers,et al.  Aggregation State‐Dependent Activation of the Classical Complement Pathway by the Amyloid β Peptide , 1997, Journal of neurochemistry.

[85]  P. Mcgeer,et al.  Complement activation by beta-amyloid in Alzheimer disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[86]  K. Blennow,et al.  Clinical Heterogeneity of Probable Alzheimer's Disease , 1992, Journal of geriatric psychiatry and neurology.

[87]  S. Eisenberg,et al.  Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. , 1991, The Journal of biological chemistry.

[88]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.